Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

458 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI; HEP-COVID Investigators. Spyropoulos AC, et al. Among authors: halperin jl. JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203. JAMA Intern Med. 2021. PMID: 34617959 Free PMC article. Clinical Trial.
Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial.
Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Sharifova G, Cohen M, Lund JM, Mignatti A, Gianos E, Tafur A, Lewis PA, Cohoon K, Kittelson JM, Lesser ML, Sison CP, Rahman H, Ochani K, Hiatt WR, Dale RA, Anderson VE, Bonaca M, Halperin JL, Weitz JI, Spyropoulos AC. Goldin M, et al. Among authors: halperin jl. Thromb Haemost. 2021 Dec;121(12):1684-1695. doi: 10.1055/a-1475-2351. Epub 2021 May 28. Thromb Haemost. 2021. PMID: 33823560
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators. Spyropoulos AC, et al. Among authors: halperin jl. N Engl J Med. 2018 Sep 20;379(12):1118-1127. doi: 10.1056/NEJMoa1805090. Epub 2018 Aug 26. N Engl J Med. 2018. PMID: 30145946 Free article. Clinical Trial.
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older.
Ageno W, Lopes RD, Goldin M, Yusen RD, Albers GW, Elliott GC, Halperin JL, Hiatt WR, Maynard G, Steg PG, Weitz JI, Suh E, Lu W, Barnathan ES, Raskob GE, Spyropoulos AC. Ageno W, et al. Among authors: halperin jl. J Thromb Haemost. 2021 Nov;19(11):2772-2780. doi: 10.1111/jth.15477. Epub 2021 Aug 17. J Thromb Haemost. 2021. PMID: 34314574 Free PMC article. Clinical Trial.
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial.
Goldenberg NA, Kittelson JM, Abshire TC, Bonaca M, Casella JF, Dale RA, Halperin JL, Hamblin F, Kessler CM, Manco-Johnson MJ, Sidonio RF, Spyropoulos AC, Steg PG, Turpie AGG, Schulman S; Kids-DOTT Trial Investigators and the ATLAS Group. Goldenberg NA, et al. Among authors: halperin jl. JAMA. 2022 Jan 11;327(2):129-137. doi: 10.1001/jama.2021.23182. JAMA. 2022. PMID: 35015038 Free PMC article. Clinical Trial.
Vorapaxar, combination antiplatelet therapy, and stroke.
Hart RG, Halperin JL, Weitz JI. Hart RG, et al. Among authors: halperin jl. J Am Coll Cardiol. 2014 Dec 9;64(22):2327-9. doi: 10.1016/j.jacc.2014.09.038. Epub 2014 Dec 1. J Am Coll Cardiol. 2014. PMID: 25465418 Free article. No abstract available.
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients.
Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Lu W, Spiro TE, Barnathan ES, Raskob GE. Spyropoulos AC, et al. Among authors: halperin jl. J Am Coll Cardiol. 2020 Jun 30;75(25):3140-3147. doi: 10.1016/j.jacc.2020.04.071. J Am Coll Cardiol. 2020. PMID: 32586587 Free PMC article. Clinical Trial.
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Spyropoulos AC, Raskob GE, Cohen AT, Ageno W, Weitz JI, Spiro TE, Lu W, Lipardi C, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard G, Steg PG, Sugarmann C, Barnathan ES. Spyropoulos AC, et al. Among authors: halperin jl. Circulation. 2022 May 10;145(19):1471-1479. doi: 10.1161/CIRCULATIONAHA.121.057847. Epub 2022 Apr 7. Circulation. 2022. PMID: 35389229 Free article.
Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness.
Raskob GE, Ageno W, Albers G, Elliott CG, Halperin J, Maynard G, Steg PG, Weitz JI, Albanese J, Yuan Z, Levitan B, Lu W, Suh EY, Spiro T, Lipardi C, Barnathan ES, Spyropoulos AC. Raskob GE, et al. J Am Heart Assoc. 2022 Oct 18;11(20):e026229. doi: 10.1161/JAHA.122.026229. Epub 2022 Oct 7. J Am Heart Assoc. 2022. PMID: 36205248 Free PMC article. Clinical Trial.
Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial.
Spyropoulos AC, Goldin M, Ageno W, Albers GW, Elliott CG, Hiatt WR, Halperin JL, Maynard G, Steg PG, Weitz JI, Spiro TE, Lu W, Marsigliano J, Raskob GE, Barnathan ES. Spyropoulos AC, et al. Among authors: halperin jl. TH Open. 2022 Jul 11;6(3):e177-e183. doi: 10.1055/s-0042-1750379. eCollection 2022 Jul. TH Open. 2022. PMID: 36046208 Free PMC article.
458 results